GH Research (GHRS) Stock Forecast, Price Target & Predictions
GHRS Stock Forecast
GH Research stock forecast is as follows: an average price target of $28.00 (represents a 308.76% upside from GHRS’s last price of $6.85) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
GHRS Price Target
The average price target for GH Research (GHRS) is $28.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $28.00. This represents a potential 308.76% upside from GHRS's last price of $6.85.
GHRS Analyst Ratings
According to 2 Wall Street analysts, GH Research's rating consensus is 'Buy'. The analyst rating breakdown for GHRS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
GH Research Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 18, 2024 | Sumant Kilkami | Canaccord Genuity | $28.00 | $9.26 | 202.52% | 308.76% |
| May 06, 2024 | Sumant Kilkami | Canaccord Genuity | $31.00 | $11.68 | 165.41% | 352.55% |
The latest GH Research stock forecast, released on Nov 18, 2024 by Sumant Kilkami from Canaccord Genuity, set a price target of $28.00, which represents a 202.52% increase from the stock price at the time of the forecast ($9.26), and a 308.76% increase from GHRS last price ($6.85).
GH Research Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 2 |
| Avg Price Target | $28.00 | $28.00 | $29.50 |
| Last Closing Price | $6.85 | $6.85 | $6.85 |
| Upside/Downside | 308.76% | 308.76% | 330.66% |
In the current month, the average price target of GH Research stock is $28.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 308.76% increase as opposed to GH Research's last price of $6.85. This month's average price target is down 0.00% compared to last quarter, and down -5.08% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 18, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 06, 2024 | Canaccord Genuity | Buy | Buy | Hold |
GH Research's last stock rating was published by Canaccord Genuity on Nov 18, 2024. The company gave GHRS a "Buy" rating, the same as its previous rate.
GH Research Financial Forecast
GH Research Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
GH Research's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. GHRS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
GH Research EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict GHRS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than GH Research's previous annual EBITDA (undefined) of $NaN.
GH Research Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-13.53M | $-13.53M | $-13.01M | $-12.49M | $-11.53M | $-12.80M | $-11.45M |
| High Forecast | $-13.53M | $-13.53M | $-13.01M | $-12.49M | $-9.89M | $-12.80M | $-11.45M |
| Low Forecast | $-13.53M | $-13.53M | $-13.01M | $-12.49M | $-12.63M | $-12.80M | $-11.45M |
| Surprise % | - | - | - | - | - | - | - |
GH Research's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GHRS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
GH Research SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
GH Research's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to GHRS last annual SG&A of $NaN (undefined).
GH Research EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.26 | $-0.26 | $-0.25 | $-0.24 | $-0.22 | $-0.25 | $-0.22 |
| High Forecast | $-0.26 | $-0.26 | $-0.25 | $-0.24 | $-0.19 | $-0.25 | $-0.22 |
| Low Forecast | $-0.26 | $-0.26 | $-0.25 | $-0.24 | $-0.24 | $-0.25 | $-0.22 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, GH Research's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GHRS previous annual EPS of $NaN (undefined).
GH Research Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HOWL | Werewolf Therapeutics | $1.64 | $12.00 | 631.71% | Buy |
| PEPG | PepGen | $4.30 | $29.50 | 586.05% | Buy |
| MOLN | Molecular Partners | $5.25 | $29.00 | 452.38% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| RLAY | Relay Therapeutics | $4.50 | $18.00 | 300.00% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| GHRS | GH Research | $8.46 | $28.00 | 230.97% | Buy |
| GPCR | Structure Therapeutics | $31.48 | $99.00 | 214.49% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| ANNX | Annexon | $4.88 | $14.00 | 186.89% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| PHVS | Pharvaris | $18.49 | $42.00 | 127.15% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| RCUS | Arcus Biosciences | $16.08 | $31.71 | 97.20% | Buy |
| DSGN | Design Therapeutics | $6.25 | $9.67 | 54.72% | Buy |
| RZLT | Rezolute | $4.44 | $6.67 | 50.23% | Buy |
| JANX | Janux Therapeutics | $59.61 | $70.25 | 17.85% | Buy |
| IKNA | Ikena Oncology | $1.62 | $1.33 | -17.90% | Buy |